Menu Search
Equities

Eom Pharmaceutical Holdings Inc

IMUC:PKL

Eom Pharmaceutical Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.105
  • Today's Change-0.095 / -47.50%
  • Shares traded1.21k
  • 1 Year change-68.18%
  • Beta0.4280
Data delayed at least 15 minutes, as of Nov 21 2024 20:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2021, Eom Pharmaceutical Holdings Inc increased its cash reserves by 465.28%, or 1.22m. Cash Flow from Financing totalled 3.53m or -- of revenues. In addition the company used 2.31m for operations while cash used for investing totalled .
Cash flow per share--
Price/Cash flow per share--
Book value per share-0.0212
Tangible book value per share-0.0212
More ▼

Balance sheet in USDView more

Eom Pharmaceutical Holdings Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money. Eom Pharmaceutical Holdings Inc has considerable financial risk.
Current ratio1.51
Quick ratio--
Total debt/total equity--
Total debt/total capital7.41
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.